Last reviewed · How we verify
Clarithromycin Extended Release
At a glance
| Generic name | Clarithromycin Extended Release |
|---|---|
| Also known as | placebo Biaxin, Clarithromycin, Klaricid ER 500 (sequential) |
| Sponsor | University Medical Center Groningen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions (PHASE1)
- Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions. (PHASE1)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 (PHASE2, PHASE3)
- Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis (PHASE3)
- Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis (PHASE3)
- A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clarithromycin Extended Release CI brief — competitive landscape report
- Clarithromycin Extended Release updates RSS · CI watch RSS
- University Medical Center Groningen portfolio CI